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Recombinant viral proteinDengue viruses (DENV) are the etiological agents of dengue fever (DF) and dengue hemorrhagic fever (DHF).
The DENV complex consists of four closely related viruses designated DENV serotypes 1 through 4. Although
infection with one serotype induces cross reactive antibody to all 4 serotypes, the long-term protective
antibody response is restricted to the serotype responsible for infection. Cross reactive antibodies appear to
enhance infection during a second infection with a different serotype. The goal of the present study was to
characterize the binding speciﬁcity and functional properties of human DENV immune sera. The study
focused on domain III of the viral envelope protein (EDIII), as this region has a well characterized epitope that
is recognized by strongly neutralizing serotype-speciﬁc mouse monoclonal antibodies (Mabs). Our results
demonstrate that EDIII-reactive antibodies are present in primary and secondary DENV immune human sera.
Human antibodies bound to a serotype speciﬁc epitope on EDIII after primary infection and a serotype cross
reactive epitope on EDIII after secondary infection. However, EDIII binding antibodies constituted only a
small fraction of the total antibody in immune sera binding to DENV. Studies with complete and EDIII
antibody depleted human immune sera demonstrated that EDIII binding antibodies play a minor role in
DENV neutralization. We propose that human antibodies directed to other epitopes on the virus are primarily
responsible for DENV neutralization. Our results have implications for understanding protective immunity
following natural DENV infection and for evaluating DENV vaccines.© 2009 Elsevier Inc. All rights reserved.Introduction
Dengue viruses (DENVs) are emerging, mosquito-borne ﬂavi-
viruses and the causative agents of dengue fever (DF) and dengue
hemorrhagic fever (DHF). The DENV complex consists of four
serotypes designated DENV1 through 4. A person infected with
DENV develops antibodies that cross react with all four serotypes
(Roehrig, 2003). However, the antibodies only provide long-term
protection against the serotype responsible for the original infection
and people can be infected a second time with a different serotype
(Halstead, 2002; Rothman, 2004). Individuals experiencing secondary
DEN infections face a greater risk of developing severe disease
(Halstead, 2002; Rothman, 2004). A leading theory to explain the
greater risk of severe diseasewith secondary DEN infection is that pre-
existing cross reactive antibodies bind to the virus and enhance
infection of Fc-receptor bearing cells (Halstead, 2003). Despite the fact
that DEN vaccines are entering large scale clinical testing, we know).
ll rights reserved.remarkably little about the relationship between the binding proper-
ties of DEN antibodies in human immune sera and the functional
outcome of these interactions.
The major target of ﬂavivirus neutralizing antibody is the
Envelope (E) protein, although membrane protein (M) and non-
structural protein 1 (NS1) antibodies have also been shown to be
protective (Roehrig, 2003; Schlesinger, Brandriss, and Walsh, 1987;
Vázquez et al., 2002). E protein is responsible for viral attachment to
host cells and the low pH fusion of viral and host cell membranes.
The crystal structures of E of several ﬂaviviruses have been solved
(Modis et al., 2003; Modis et al., 2005; Nybakken et al., 2006; Rey et
al., 1995). Individual subunits of E consist of three beta-barrel
domains designated E domains I (EDI), II (EDII) and III (EDIII).
Native E is a homodimer that lies ﬂat on the surface of the viral
membrane.
Our current understanding of the interactions between DENV and
antibody is largely based on studies with mouse monoclonal
antibodies (Mabs). DENV neutralizing mouse Mabs have been
mapped to all three domains of E. In general, strongly neutralizing
mouse Mabs are DENV serotype-speciﬁc and bind to an epitopes on
EDIII that is unique to each serotype (Crill and Roehrig, 2001;
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Roehrig, Bolin, and Kelly, 1998; Sukupolvi-Petty et al., 2007). A DENV
type speciﬁc epitope on EDIII bound by strongly neutralizing Mabs
has been mapped to 4 loops on the lateral face of EDIII
(Gromowski and Barrett, 2007; Gromowski, Barrett, and Barrett,
2008; Sukupolvi-Petty et al., 2007). Investigators have also mapped
ﬂavivirus cross reactive epitopes on EDIII (Gromowski, Barrett, and
Barrett, 2008; Sukupolvi-Petty et al., 2007). Unlike DENV type
speciﬁc Mabs, cross reactive Mabs that bind to EDIII have moderate
to weak neutralizing activity.
Despite the large body of work with mouse Mabs, remarkably
little work has been done to characterize the binding properties of
human DENV immune sera and to understand the relationship
between human antibody binding and neutralization. Convalescent
sera from people and horses naturally infected with West Nile
virus (WNV), a related ﬂavivirus, had low levels of EDIII-reactive
antibody (Oliphant et al., 2007; Sanchez et al., 2007). In WNV
immune sera, EDIII binding antibodies were not primarily respon-
sible for neutralization activity (Oliphant et al., 2007; Sanchez et
al., 2007). People who have recovered from DENV infections also
develop EDIII-reactive antibodies (Beasley et al., 2004; Crill et al.,
2009; Hapugoda et al., 2007; Holbrook, Shope, and Barrett, 2004;
Ludolfs et al., 2002); however, most human antibody appears to be
directed towards a ﬂavivirus cross reactive epitope close to the
fusion loop in EDII of DENV (Crill et al., 2009; Lai et al., 2008). To
date, no studies have been done to directly test if EDIII-reactive
antibodies are primarily responsible for the neutralizing activity of
human DENV immune sera. The goal of this study was to measure
the level and speciﬁcity of EDIII-reactive antibodies in people who
have recovered from primary and secondary DENV infections and
to determine the contribution of EDIII-reactive antibodies to DENV
neutralization.
Results
Dengue immune human sera were obtained by collecting blood
samples fromvolunteers whomight have been infected during foreign
travel. Of 35 subjects enrolled in the study, 17 had antibodies that
neutralized one or more DENV serotypes. The neutralization patterns
of the 17 immune subjects were consistent with past exposures to
DENV1 only (one subject), DENV2 only (four subjects), DENV3 only
(four subjects) and secondary DENV infections (eight subjects). These
sera were also tested for DENV neutralizing antibody by the Centers
for Disease Control (CDC) in Fort Collins, CO and the Laboratory of
Infectious Diseases, National Institute of Allergy and Infectious
Diseases (NIAID), Bethesda, Maryland. The CDC and NIAID labora-
tories reached the same conclusions as we did about the past infection
history of these subjects (unpublished data from Drs Robert Lanciotti,
CDC and Steve Whitehead, NIH). For the current study we selected 6
sera representing 2 subjects each who had recovered from primary
DENV2, primary DENV3 and secondary DENV infections. The DENV
neutralization titers and the most likely year and place of infection of
these subjects are listed in Table 1.Table 1
Human DENV immune sera used in the study.
Sample ID Likely year and place
of infection
Time interval between infection
and sample collection
P
D
01b Sri Lanka, 1996 9 years b
13 South Paciﬁc Island, 1997 8 years
11 El Salvador, 1998 7 years
03 Thailand, 2001 4 years
09 India or Sri Lanka, 2000 5 years N
24 Brazil, 1998 7 years N
a The plaque reduction 50 % neutralization titer was determined using Vero cells.
b DENV serotype 2 was isolated from serum sample in 1996.DENV binding antibodies in human immune sera
Experiments were performed to measure the binding properties of
antibodies in the 6 selected immune sera to puriﬁed DENV2 and 3. The
immune sera were tested at four fold dilutions starting at 1:50.
Antibodies in human DENV immune sera cross reacted with both
serotypes indicating that the dominant antibodies after primary and
secondary infection are serotype cross reactive (Fig.1). End point virus
binding titers were calculated for the 6 sera (Table 2). As expected,
subjects with secondary infections had higher titers than subjects
with primary infections (Table 2). These results indicate that an ELISA
with whole virus as antigen mainly detects serotype cross reactive
antibodies and the assay is not predictive of the neutralization
properties of the serum sample or past infection history of the subject.
The DENV particle is made up of envelope (E), membrane (M) and
capsid (C) proteins. As E protein is the main target of neutralizing
antibody, experiments were done to compare the antibody response
to E protein and whole virions. As full length E protein alone is not
secreted out of cells, we expressed the soluble ectodomain of E (Es)
from DENV3 to be used as an antigen. We used immune serum
samples # 003 and 011 from primary DENV3 cases and # 009 and 024
from secondary cases and compared binding to DENV3 and Es from
DENV3. Antibodies in human immune sera bound well to both Es and
virus particles, but greater binding was observed with virus particles
compared to Es (Fig. 2). These results demonstrate that although the
ectodomain of E is a dominant target of antibody, virions contain
epitopes that are absent in recombinant Es.
Puriﬁcation and characterization of recombinant DENV envelope protein
domain III (EDIII)
Studies with mouse Mabs have demonstrated that most DENV
serotype-speciﬁc antibodies bind to EDIII (Crill and Roehrig, 2001;
Gromowski and Barrett, 2007; Lin et al., 1994; Lok et al., 2008;
Roehrig, Bolin, and Kelly, 1998; Sukupolvi-Petty et al., 2007). When
using whole virus antigen in an ELISA, the cross reactive antibodies in
human immune sera are likely to dominate and mask signal
originating from serotype-speciﬁc antibodies. To develop an assay
for measuring serotype-speciﬁc antibody, recombinant EDIII was
expressed as a MBP fusion protein in Escherichia coli (Fig. 3). Previous
studies have demonstrated that EDIII expressed alone or as a MBP
fusion protein is folded correctly and displays antibody epitopes
present on the virion (Maillard et al., 2008; Volk et al., 2004; Volk et
al., 2007; Yu et al., 2004). To conﬁrm that recombinant DENV2 and 3
MBP-EDIII fusion proteins produced in our laboratory were correctly
folded, binding assays were performed with eight mouse Mabs that
bind to EDIII of DENV2 and/or 3. Mabs 3H5-1, 9F16 and 2Q1899 are
antibodies that bind to serotype-speciﬁc epitopes on the lateral ridge
of DENV2 (Gromowski and Barrett, 2007; Henchal et al., 1985;
Sukupolvi-Petty et al., 2007). As predicted, all three antibodies bound
to MBP-EDIII from DENV2 but not DENV3 (Table 3). We used mouse
Mabs 8A1, 14A4 and 1H9 which are serotype-speciﬁc neutralizing
antibodies that bind to EDIII from DENV3 only (Seraﬁn and Aaskov,RNT50 titera Most probable past
infectionENV1 DENV2 DENV3 DENV4
1:20 1:271 b1:20 1:42 Primary DENV2 infection
1:178 N1:1280 1:65 1:140 Primary DENV2 infection
1:84 1:124 1:1032 1:169 Primary DENV3 infection
1:30 1:87 1:338 b1:20 Primary DENV3 infection
1:1280 N1:1280 1:290 1:393 Secondary DENV infection
1:1280 1:640 1:64 1:108 Secondary DENV infection
Fig. 1. Binding of human immune sera to puriﬁed DENV2 and 3. The binding of antibodies in convalescent sera from patients who have recovered from primary DENV2 infections (A,
B), primary DENV3 infections (C, D) and secondary DENV infections (E, F) to puriﬁed DENV2 (solid lines) or DENV3 (dashed line) was analyzed by ELISA. The data points represent
mean values and the error bars represent the standard error of the mean. The data shows one of two representative experiments.
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1H9 bind to the lateral ridge of EDIII from DENV3, whereas the 14A4
epitope on DENV3 EDIII has not beenmapped yet. Mabs 8A1,14A4 and
1H9 bound to MBP-EDIII from DENV3 but not DENV2 (Table 3). We
also used two Mabs that bind to a serotype cross reactive epitopes in
EDIII and these two antibodies bound to both recombinant proteins
(Table 3). Thus, the type speciﬁc and cross reactive epitopes on EDIII
of DENV are preserved in the recombinant proteins used in the
current study.
EDIII-reactive antibodies in human DENV immune sera
After conﬁrming that the recombinant EDIII-MBP fusion proteins
expressed appropriate serotype-speciﬁc and cross reactive epitopes,
the antigens were used to detect EDIII-reactive antibody in our panel
of human DENV immune sera. Each immune serumwas tested in fourfold dilutions starting at 1:12.5. At high concentrations of serum,
antibodies in the two subjects with evidence of past primary DENV2
infections bound to EDIII from DENV2 better than EDIII from DENV3
(Figs. 4A and B). Similarly, antibodies in the two subjects with
serotype-speciﬁc neutralizing antibody to DENV3 bound to EDIII from
DENV3 better than EDIII from DENV2 (Figs. 4C and D). The two
subjects with evidence of past secondary DENV infections had
antibodies that bound equally well to both antigens (Figs. 4E and F).
These results demonstrate that EDIII-reactive antibodies that devel-
oped after primary infection were speciﬁc to the serotype responsible
for infection. The EDIII end point binding titers also displayed
serotype-speciﬁcity after primary infection (Table 2). In the case of
secondary serum samples, the EDIII end point titers were similar for
both antigens (Table 2).
We compared the amount of antibody in immune sera directed to
the whole virus versus EDIII. To measure relative amounts of available
Fig. 2. Binding of human immune sera to puriﬁed DENV3 and the ectodomain of E protein. To compare antibody binding to whole virions and E protein, ELISA plates were
coated with puriﬁed DENV3 or the ectodomain of E protein (Es) from DENV3. As a negative control, plates were coated with chloramphenicol acetyl transferase (CAT) protein.
Sera from patients who have recovered from primary DENV3 infections (03 and 011) and secondary DENV infections (09 and 024) were used to measure virus and E protein
speciﬁc antibody responses. The data shows one of two representative experiments.
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binding assays, end point titers were calculated using MAbs 8A5 and
12C1 (Table 3), which bind to a conserved DENV complex epitope on
EDIII. The endpoint titers were 5–10 times higher for recombinantFig. 3. Puriﬁcation and characterization of recombinant MBP-EDIII fusion proteins from
DENV2 and 3. The recombinant protein expressed in E. coli and puriﬁed by amylase
afﬁnity chromatography. Lanes 1 and 3 depict the DENV2 and DENV3 MBP-EDIII fusion
proteins in E. coli lysates. Lanes 2 and 4 depict the puriﬁed protein obtained after
amylase afﬁnity chromatography. The arrow indicated the band corresponding to the
53 kDa MBP-EDIII fusion protein.EDIII compared to virus (Table 2). This result was expected because
the DENV complex epitope on EDIII has been mapped to the A–B loop,
which is poorly exposed on the intact virus but not on recombinant
EDIII (Sukupolvi-Petty et al., 2007). Despite the superior binding of
8A5 and 12C1 to recombinant EDIII, human immune sera bound
poorly to recombinant EDIII compared to the virus antigen (Table 2).
After primary infections the serotype-speciﬁc EDIII-reactive anti-
bodies ranged from 0.1 to 8.1% of total virus reactive antibodies (Table
2). Following secondary infections the EDIII-reactive antibodies
accounted for 0.2 to 4.0% of total virus reactive antibodies. These
results indicate that subjects who have recovered from DENV
infections have low levels of EDIII-reactive antibody and, in the case
of primary infections, antibodies are directed to serotype-speciﬁc
epitope(s) on EDIII.
Role of EDIII-reactive antibodies in DENV neutralization
Experiments were performed to determine the contribution of
EDIII-reactive antibodies in human immune sera to DENV neutraliza-
tion. The immune sera were depleted of EDIII binding antibodies by
incubating the serum samples with MBP-EDIII bound to an amylose
resin. The primary DENV2 and DENV3 immune sera were incubated
with MBP-EDIII from DENV2 or DENV3, respectively. The secondary
sera were treated with MBP-EDIII from DENV2 (Sample 009) or
DENV3 (Sample 024). As depicted in Fig. 5, incubation with
recombinant MBP-EDIII removed most of the EDIII-reactive antibody.
The treatment speciﬁcally removed EDIII-reactive antibodies as sera
treated with MBP alone were indistinguishable from untreated
immune sera (Fig. 5). Interestingly, when the secondary sera were
depleted using MBP-EDIII from one serotype, most EDIII reactivity to
the second serotype was also lost (data not shown) indicating that in
Table 2
Titer of DENV and EDIII-reactive antibody in immune sera.
Serum sample
or mouse Mab
Most probable
past infection
Binding to DENV
(end point titer)a
Binding to EDIII
(end point titer)a
Amount of EDIII antibody relative
to whole virus antibody (%)b
DENV2 DENV3 DENV2 EDIII DENV3 EDIII DENV2 EDIII DENV3 EDIII
Serum 01 Primary DENV2 9864 8658 67 11 0.7 0.1
Serum 13 Primary DENV2 11,997 4509 975 45 8.1 1.0
Serum 03 Primary DENV3 1931 4813 3 50 0.2 1.0
Serum 11 Primary DENV3 7119 8658 0 37 0.0 0.4
Serum 09 Secondary DENV 69,840 74,549 487 164 0.7 0.2
Serum 24 Secondary DENV 53,798 81,411 2153 2378 4.0 2.9
Mab 8A5c NAd 308 161 1096 1778 NA NA
Mab 12C1c NA 554 195 2455 2884 NA NA
a End point titer was calculated from curves displayed in Figs. 1 and 3. The end point titer is the reciprocal of the highest dilution that gave a signal greater than 3 standard
deviations of the signal for normal human serum.
b The amount of EDIII antibody relative to whole virus binding antibody was determined using the following formula: (EDIII end point titer /DENV end point titer)×100.
c To compare accessible EDIII epitopes on viral and recombinant protein antigens from DENV2 and DENV end point binding titers were calculated for 2 mouse Mabs that bind to an
epitope on EDIII that is conserved in all 4 serotypes. Both antibodies were used at a starting concentration of 8 μg/ml and tested at 8 four fold dilutions.
d Not applicable.
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cross reactive epitope on EDIII.
As the recombinant EDIII used in above studies was expressed as a
MBP fusion protein, it was conceivable that some human antibody
epitopes in EDIII were altered or masked by the fusion partner. To
determine if MBP fusion partner altered important epitopes on EDIII,
binding assays were performed with puriﬁed DENV2 EDIII without
MBP (kindly provided by Dr. Michael Diamond, Washington Uni-
versity, St. Louis). Dengue immune sera absorbed with recombinant
DENV2 EDIIII-MBP were tested for the presence of antibodies that
bound to EDIII without MBP. As depicted in Fig. 6, immune sera
absorbed with DENV2 MBP-EDIII protein failed to bind recombinant
DENV2 EDIII without MBP indicating that the MBP fusion partner does
not alter or mask the main human antibody epitopes on EDIII.
Next, untreated and EDIII antibody depleted serawere tested in the
ﬂow cytometry based DENV neutralization assay with U937 cells
expressing DC-SIGN. Fig. 7 depicts neutralization curves for primary
DENV2, primary DENV3 and secondary DENV immune sera. Serum
samples with or without EDIII-reactive antibodies showed similar
neutralization patterns (Fig. 7). The 50% neutralization titers were
∼10–15% lower for serum samples depleted with EDIII compared to
the MBP treated sera (Table 4). These results indicate that EDIII-
reactive antibodiesmake aminor contribution to the total neutralizing
capacity of human DENV immune sera (Table 4).
As it was conceivable that EDIII antibodies might play an important
role in DENV neutralization in some cell types but not others, some of
the experiments with U937 cells expressing DC-SIGN (Table 4) were
repeated with Vero cells. We selected EDIII antibody depleted serumTable 3
Binding of DENV neutralizing monoclonal antibodies to recombinant MBP-EDIII fusion prot
Neutralizing monoclonal
antibody
Binding speciﬁcity
3H5-1 DENV2 type speciﬁc, EDIII lateral ridge epitope
9F16 DENV2 type speciﬁc, EDIII lateral ridge epitope
2Q1899 DENV2 type speciﬁc, EDIII lateral ridge epitope
1H9 DENV3 type speciﬁc EDIII lateral ridge epitope
8A1 DENV3 type speciﬁc, EDIII lateral ridge epitope
14A4 DENV3 type speciﬁc, EDIII epitope
8A5 DENV cross reactive EDIII epitope
12C1 DENV cross reactive, EDIII epitope
a A positive value was deﬁned as 0.2 OD units above the background signal obtained witsample # 003 (primary DENV3 immune) and # 009 (secondary DENV
immune) and performed neutralization assays with Vero cells. In the
case of sample #003, the neutralization titers for DENV3 were similar
for untreated and EDIII antibody depleted serum (50% neutralization
titers of 74 and 88 respectively). Similarly, for sample #009, the
neutralization titers for DENV2 were similar (50% neutralization titers
of 895 and 858 respectively) for untreated and EDIII antibody
depleted sera. These results demonstrate that EDIII-reactive anti-
bodies were not required to neutralize DENV infection of U937 cells
and Vero cells.
Discussion
Despite many publications on interactions between DENV and
antibody, surprisingly few studies have been published as to how the
binding properties of human antibodies relate to DENV neutralization.
The goal of the current study was to characterize the speciﬁcity and
functionality of antibodies in DENV immune human sera. Here we
have demonstrated that EDIII-reactive antibodies are present in
human immune sera. The EDIII antibodies mainly recognized a type
speciﬁc epitopes after primary infection and a cross reactive epitope
after secondary infection. EDIII binding antibodies were a minor
component of the total antibodies in immune sera binding to DENV.
Recently Crill et al. used DENV2 virus like particles to measure
epitopes speciﬁc human antibody responses and they also observed
low levels of EDIII binding antibodies in human sera (Crill et al., 2009).
Our results demonstrate that EDIII binding antibodies make only a
minor contribution to the total neutralizing capacity of humaneins.
Reference Binding to recombinant
MBP-EDIII fusion proteins of
DENV2 DENV3
Gromowski and Barrett (2007);
Sukupolvi-Petty et al. (2007);
Henchal et al. (1985)
+a −
Gromowski and Barrett (2007);
Sukupolvi-Petty et al. 2007)
+ −
Gromowski and Barrett (2007);
Sukupolvi-Petty et al. (2007)
+ −
Seraﬁn and Aaskov (2001)
Unpublished
− +
Unpublished − +
Unpublished − +
Unpublished + +
Unpublished + +
h the MBP antigen alone.
Fig. 4. Binding of human immune sera to MBP-EDIII from DENV2 or 3. Convalescent sera from 2 people each who had recovered from primary DENV2 (A, B), primary DENV3 (C, D)
and secondary DENV (E, F) infections were tested for binding to recombinant MBP-EDIII from DENV2 (solid lines) or DENV3 (dashed line). The data points represent the mean values
and the error bars represent the standard error of the mean. The data are from one of two representative experiments.
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focus of much recent work (Gromowski and Barrett, 2007; Gro-
mowski, Barrett, and Barrett, 2008; Sukupolvi-Petty et al., 2007) were
not the target of most neutralizing antibody in primary and secondary
DENV immune sera.
Several investigators have reported the presence of EDIII-reactive
antibodies following natural infection of people and animals with
ﬂaviviruses (Beasley et al., 2004; Hapugoda et al., 2007; Holbrook,
Shope, and Barrett, 2004; Ludolfs et al., 2002; Sanchez et al., 2007). In
human WNV immune sera EDIII-reactive antibodies were present,
although at low levels compared to the total antibody binding to virus
(Oliphant et al., 2007). Furthermore, investigators have shown that
EDIII-reactive antibodies are speciﬁc for the infecting virus, unlike
antibodies against the whole virus particle, which are highly cross
reactive (Beasley et al., 2004; Hapugoda et al., 2007; Holbrook, Shope,
and Barrett, 2004; Ludolfs et al., 2002; Sanchez et al., 2007). Our data
reported here indicate that DENV cross reactive antibodies dominatein whole virus binding assays. Our data demonstrate that in subjects
who have recovered from primary DENV infection, EDIII-reactive
antibodies weremainly directed to an epitope speciﬁc for the serotype
responsible for infection, whereas in secondary cases EDIII-reactive
antibodies bound to a DENV cross reactive epitope. Recent studies
withmouseMabs havemapped the location of both cross reactive and
serotype speciﬁc epitopes on DENV EDIII (Gromowski and Barrett,
2007; Gromowski, Barrett, and Barrett, 2008; Sukupolvi-Petty et al.,
2007). Although it is reasonable to speculate that the cross reactive
and serotype speciﬁc epitopes deﬁned bymouse Mabs are also targets
of the human antibody response measured here, further studies are
needed to conﬁrm this.
Currently, the primary serological assay to identify the DENV
serotype responsible for a primary infection is the neutralization
test, which is a laborious and time consuming assay. Our results
indicate that a simple ELISA with recombinant EDIII as antigen can
be used to identify the DENV serotype responsible for primary
Fig. 5. Depletion of EDIII-reactive antibody from human immune sera. Immune sera
were from subjects who had have recovered from primary DENV2 (panel A), primary
DENV3 (panel B) or secondary DENV (panel C) infections. The serawere absorbed using
MBP alone or recombinant MBP-EDIII-fusion protein from DENV2 (sera # 001, 009 and
013) or DENV3 (sera #003, 011 and 024).
Fig. 6. Binding of EDIII antibody depleted dengue immune sera to DENV2 EDIII without
a MBP fusion partner. Dengue immune sera (#13 and #24) were absorbed using DENV2
MBP-EDIII or MBP alone. The absorbed sera were tested for binding to DENV2 EDIII
expressed without a MBP fusion partner. The MBP-EDIII absorbed sera failed to bind to
EDIII alone indicating that EDIII with or without a MBP expressed similar antibody
epitopes.
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reactive antibodies is preserved in both early (within ﬁrst year) and
late (N4 years after infection) convalescent primary sera (data not
shown). In secondary infections, this assay is unlikely to predict
responsible serotypes as the response is directed to cross reactive
epitope(s) on EDIII. Ludolfs et al. also reported similar results using
recombinant EDIII in an immunoblot assay with human immune
sera (Ludolfs et al., 2002). Further studies are needed to evaluate
the utility of recombinant EDIII as an antigen for identifying DENVs
responsible for primary infection. In the case of secondary
infections, studies need to address if the EDIII-reactive antibodies
simply cross react with the serotypes responsible for the primary
and secondary infections or if they also cross react with serotypes
not responsible for infection.
Studies with mouse Mabs have led to the identiﬁcation and
mapping of a serotype-speciﬁc epitope on the lateral ridge of EDIII of
several ﬂaviviruses including DENV (Gromowski and Barrett, 2007;
Nybakken et al., 2005; Roehrig, 2003; Sukupolvi-Petty et al., 2007). An
implicit, but untested assumption has been that antibodies directed to
this epitope must play a role in serotype-speciﬁc neutralizationfollowing natural human infection. Our results demonstrate that
DENV-speciﬁc EDIII-reactive antibodies play a minor role in neutra-
lization observed with human sera. Studies with immune sera from
people and horses naturally infected with WNV have also revealed a
variable role for EDIII-reactive antibodies in viral neutralization
(Oliphant et al., 2007; Sanchez et al., 2007). In some cases, EDIII-
reactive antibody depletion led to a decrease in WNV neutralization
whereas in other cases no signiﬁcant change was observed (Oliphant
et al., 2007; Sanchez et al., 2007). Our results do not rule out the
possibility of inter domain epitopes involving EDIII making important
contributions to neutralization as these epitopes would not be present
in the recombinant EDIII proteins used in the current study. We
conclude that antibodies directed to inter domain epitopes, epitopes
on EDI or II of E protein and, possibly M protein, are mainly
responsible for the neutralizing activity of human immune sera.
One potential concern is that the recombinant EDIII-MBP fusion
proteins used here may be improperly folded and not display
important epitopes present on EDIII in the virus particle. Our studies
indicated that the recombinant proteins were correctly folded. Eight
EDIII-reactive mouse Mabs bound with appropriate speciﬁcity to the
recombinant EDIII from DENV2 or 3 used here indicating that the
main type speciﬁc and cross reactive neutralizing epitopes described
in the literature were present on our recombinant EDIII proteins
(Gromowski and Barrett, 2007; Gromowski, Barrett, and Barrett,
2008; Henchal et al., 1985; Seraﬁn and Aaskov, 2001; Sukupolvi-Petty
et al., 2007). Other groups have performed structure studies with
EDIII expressed alone or as a MBP-fusion protein and demonstrated
that the E. coli expressed protein has a structure similar to EDIII in its
native form (Volk et al., 2004; Volk et al., 2007; Yu et al., 2004). We
also demonstrated here that fusing EDIII to MBP did not mask or alter
the main human antibody epitopes in EDIII because human sera
absorbed with MBP-EDIII failed to bind to EDIII without the MBP
fusion portion as well.
In summary, our results indicate that EDIII-reactive antibodies
are of minor importance in neutralizing DENV by human DENV
immune sera. We propose that the major cross reactive and
serotype-speciﬁc neutralizing epitopes targeted by human immune
sera are inter domain epitopes (Goncalvez et al., 2004) and/or
located outside EDIII. Currently live attenuated DENV vaccines are
being tested in human clinical trials (Edelman, 2007). It is reason-
able to assume that the protective antibodies induced by these
vaccines will be similar to protective antibodies induced after a
natural DENV infection. We predict that the quality and quantity of
antibodies against EDIII will not determine the efﬁcacy of live
Fig. 7. DENV neutralization by human immune sera depleted of EDIII binding antibodies. Convalescent sera from 2 people each who had have recovered from primary DENV2 (A, B),
primary DENV3 (C, D) and secondary DENV (E, F) infections were depleted of EDIII binding antibody and tested for DENV neutralization at different dilutions. Neutralizing antibody
was measured using U937 cells expressing DC-SIGN and ﬂow cytometry. Neutralization curves are depicted for untreated (open circles), MBP treated (open triangles) and EDIII
antibody depleted (dark squares) sera. The data are from one of two representative experiments.
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attenuated vaccines, several groups have focused on developing
recombinant EDIII vaccines (Babu et al., 2008; Bernardo et al., 2008;
Etemad et al., 2008). Given the low levels of EDIII-reactive
antibodies detected here in human immune sera, caution is urged
in proceeding with EDIII based platforms. We currently do not
understand why people develop low levels of EDIII-reactive anti-
body after natural infection. The human immune system may
recognize and react to epitopes on EDI and EDII better than to EDIII.
However, with appropriate adjuvants and recombinant protein
constructs, it might be possible to stimulate an effective immune
response directed to relevant epitopes on EDIII as well. Such
vaccines are likely to neutralize DENV by a mechanism that is
different from neutralization observed after natural infection. Thetopic of ﬂavivirus-antibody interactions has been dominated by
studies to identify and characterize epitopes on EDIII. We hope the
results reported here will stimulate more work to characterize
epitopes on EDI and EDII and their role in DENV neutralization.
Materials and methods
Viruses
DENV1 WestPac-74, DENV2 S-16803, DENV3 CH-53489, and
DENV4 TVP-360, provided by Dr. Robert Putnak (Walter Reed Army
Institute of Research, Silver Spring, MD) were used in this study.
Working virus stocks were obtained by inoculating C6/36 mosquito
cells in tissue culture ﬂasks and growing the virus for eight days at
Table 4
DENV neutralization by immune sera depleted of EDIII-reactive antibody.
Serum
sample
Most probable
past infection
Recombinant protein used
to absorb immune sera
50% neutralization
titera
DENV2 DENV3
01 Primary DENV2 None 495 ND
MBP 495 ND
DENV2-EDIII 431 ND
13 Primary DENV2 None 375 ND
MBP 326 ND
DENV2-EDIII 283 ND
03 Primary DENV3 None ND 162
MBP ND 148
DENV3-EDIII ND 141
11 Primary DENV3 None ND 655
MBP ND 625
DENV3-EDIII ND 570
09 Secondary DENV None 1199 311
MBP 1092 326
DENV2-EDIII 907 358
24 Secondary DENV None 519 341
MBP 297 214
DENV3-EDIII 258 195
a The 50% neutralization titers were determined by using a ﬂow cytometry based
DENV neutralization assay with U937 cells expressing DC-SIGN.
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supplemented with 15% FBS and stored in aliquots at −80 °C. Viral
titers were determined by plaque assay on Vero-81 cells as previously
described (Kraus et al., 2007).
Immune sera and antibodies
Convalescent DENV immune sera were obtained from volunteers
who had experienced natural DENV infections during previous
travel abroad. The protocol for recruiting and collecting blood from
people was approved by the Institutional Review Board of the
University of North Carolina at Chapel Hill. Sera from 6 DENV
immune subjects were used in the present study. The properties of
these sera are listed in Table 1. We also used eight DENV-reactive
mouse Mabs that bind to EDIII. Mab 3H5-1, obtained from Chemicon
Co, CA, binds to EDIII of DENV2 only (Gromowski and Barrett, 2007).
Mabs 8A1 and 14A4, which bind to EDIII of DENV3, were obtained
from Dr. Robert Putnak (Walter Reed Army Institute of Research,
Silver Spring, MD). Mab 2Q1899 and 9F16 which bind to EDIII of
DENV2 were obtained from United States Biological, Massachusetts.
DENV3 EDIII-reactive Mab 1H9 was obtained from Dr John G Aaskov
(Queensland University of Technology, Australia) (Seraﬁn and
Aaskov, 2001). DENV cross reactive EDIII Mab 8A5 and 12C1 were
developed in collaboration with the South Eastern Regional Center
for Excellence in Biodefence monoclonal antibody core facility at the
University of Alabama School at Birmingham.
Puriﬁcation of DENV antigen for ELISA
DENV2 S-16803 and 3 CH53489 reference strains were grown in
Vero-81 cells (ATCC CCL-81) at 37 °C. The virus-containing media
was harvested 5–7 days after infection and centrifuged to pellet
cell debris. The clariﬁed media was laid on top of a 20% sucrose
(wt/vol) cushion and centrifuged (72,000 ×g for 5 h) to pellet the
virus. The virus pellet was allowed to dissolve overnight in PBS
before layering on a 10%–40% iodixanol gradient and being
centrifuged at 163,700 ×g for 120 min. The virus-containing
fractions were harvested. PBS was added to the virus to dilute
the iodixanol. The diluted solution was centrifuged (72,000 ×g for
5 h) to pellet the virus and remove the iodixanol. The virus pellet
was resuspended in PBS and virus protein content was estimated
by spectrometry. The virus was stored at −80 °C.Expression of the ectodomain of E protein (Es) from DENV3
RNA extracted from strain CH53489 of DENV3 was resverse
transcribed and PCR ampliﬁed to generate a PCR product containing
nucleotides coding for the last 15 amino acids of membrane protein
and the ﬁrst 415 amino acids of E protein followed by a 6 histidine tag
and a stop codon. This construct was missing the C-terminal amino
acids responsible for membrane anchoring of E protein. The PCR
product was cloned into pENTR TOPO vector (Invitrogen) and the
BaculoDirect baculovirus Expression system (Invitrogen) was used to
express recombinant protein according to manufacturer's instruc-
tions. Brieﬂy, the Es gene was recombined with BaculoDirect Liner
DNA to generate recombinant baculovirus DNA. pENTR/CAT plams-
mid was used to produce recombinant baculovirus expressing the
chloramphenicol acetyl transferase (CAT) protein, which was later
used as a negative control. Sf9 insect cells were transfected with
recombinant baculovirus DNA. P1, P2 and P3 recombinant virus stocks
were generated according to the manufacturer's instruction and
expression of protein was conﬁrmed using western blot with mouse
Mab 4G2 (for Es) or anti CAT antibodies. P3 baculovirus stocks were
used to express Es and CAT proteins.
Expression and puriﬁcation of DENV EDIII
RNAwas extracted from supernatants of cells infected with DENV2
or 3 using QIAmp Viral RNA mini Kit (Qiagen). The nucleotide
sequences encoding for EDIII of DENV2 (297-399 AA) and DENV3
(295-398 AA) were reverse transcribed and PCR ampliﬁed. The PCR
products were cloned into pMAL c2X vector (NEB) to generate
recombinant EDIII (MBP-EDIII) that is fused to maltose binding
protein (MBP) at the N terminus according to the manufacturer's
instructions. MBP-EDIII from DENV2 and DENV3 were expressed in E.
coli DH5α (Invitrogen) and puriﬁed using amylose resin afﬁnity
chromatography (NEB).
Detection of dengue reactive antibody in human immune sera by ELISA
ELISA plates were also coated with 75 ng/per well of puriﬁed
DENV2 or 3 and the ﬂavivirus cross reactive Mab 4G2 was used to
conﬁrm equal binding of each virus to the plate. ELISA plates were
coatedwith 200 ng of MBP-EDIII fromDENV2 or 3 per well. Rabbit anti
MBP sera (NEB) was used to conﬁrm equal binding of MBP-EDIII from
both serotypes to ELISA plates. ELISA plates were coated using virus or
protein recombinant protein antigen in carbonate buffer at pH 9.6 for
2 h at room temperature. The plates were washed 3 times in Tris
buffered saline with 0.2% Tween20 (TBST) and incubated with
blocking buffer (Tris buffered saline with 0.05% Tween20 containing
3% skim milk and 2% normal goat serum) at 37 °C for 1 h. After
washing the plates twice with TBST, human immune serum diluted in
blocking buffer was added to each well and incubated at 37 °C for 1 h.
Following 3 washes with TBST, alkaline phosphatase-conjugated goat
antihuman IgG (Fc-speciﬁc) (Sigma) was added to eachwell for 1 h at
37 °C. After 3 washes with TBST, p-nitrophenyl phosphate substrate
(Sigma) was added to each well and the reaction was allowed to
develop for 15 min before recording optical density at 405 nm on a
spectrophotometer. In ELISAs with mouse Mabs, the protocol was the
same except that alkaline phosphatase-conjugated goat anti-mouse
IgG was used as a secondary antibody. To compare binding to DENV2
and DENV3 antigens, we normalized the data by using the serum
sample # 24 (secondary dengue) that gave the highest OD with each
antigen (DENV2, DENV3, DENV2 EDIII and DENV3 EDIII). For each
antigen the maximumOD obtained with serum #24was deﬁned as an
OD of 1. In Figs. 1 and 4 the Y axis is referred to as relative OD to
indicate that the data was normalized using serum sample #24.
As the Es antigen bound poorly to ELISA plates, we used an antigen
capture method to compare the binding of whole virus and Es. Plates
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This antibody binds to E protein from all 4 serotypes. The antibody
coated plates were washed and incubated with blocking buffer at
37 °C for 1 h. Next, sufﬁcient DENV3 or Es antigen from DENV3 was
added to saturate antigen binding to the antibody coated plates. CAT
protein antigen was used as a negative control. The plates were
washed again before incubating with serial dilutions of dengue
immune human sera. The rest of the assaywas performed as described
above for the direct antigen coating ELISA.
Depletion of EDIII-reactive antibody in human immune sera
Puriﬁed MBP-EDIII was dialyzed against 20 mM Tris–HCl, pH 7.4,
200 mM NaCl, 1 mM EDTA (column buffer) overnight at 4 °C. MBP-
EDIII (300 μg) was incubated with the amylose resin (NEB) in column
buffer containing 3% normal human serum (NHS) and incubated
overnight at 4 °C. The resin was washed three times with column
buffer and 3 more times with PBS to remove unbound MBP-EDIII. The
resinwas blocked with 5% NHS in PBS before incubating with 1.5 ml of
human DENV immune serum diluted at 1:10 in PBS for 4 h at 37 °C.
The amylose resin was pelleted and the EDIII antibody depleted
human serum was collected. Depletion of EDIII-reactive antibodies
was conﬁrmed by ELISA with MBP-EDIII. In addition, each human
immune serum sample was absorbed to an amylose resin with MBP
alone. MBP absorbed immune sera and MBP-EDIII absorbed NHS were
used as negative controls in subsequent neutralization assays
DENV neutralization assays
DENV neutralizing antibodies was measured by plaque reduction
neutralization test (PRNT) or a ﬂow cytometry based neutralization
assay. The PRNT was performed as previously described (Kraus et al.,
2007). In brief, Vero-81 cells were seeded into 24-well plates and
grown until 80% conﬂuent. Serially diluted sera were mixed with 30
plaque forming units (PFU) of virus and incubated for 1 h at 37 °C. The
virus/serum mix was added to the Vero cells and incubated with a
nutrient overlay medium (Opti-MEM® with 1% methylcellulose and
10% FBS) for four days at 37 °C. The cells were ﬁxed and stained for
viral antigen with monoclonal antibody 4G2 as previously described
(Kraus et al., 2007). The percentage of neutralization was deﬁned as
reduction in the number of foci in the test sera compared to the
number of foci in the control wells with normal human serum. The
50% neutralization titers were determined by nonlinear dose–
response regression analysis (Prism Package, GraphPad Software,
Inc., San Diego, CA).
Flow cytometry based neutralization assays were performed in 96-
well plates with the U937 human monocytic cell line transfected with
DC-SIGN as previously described (Kraus et al., 2007). In brief, immune
sera were serially diluted and incubated with sufﬁcient virus to infect
10 to 15% of the cells in the well. The virus/serum mixture was
incubated for 1 h at 37 °C and then added to the cells for 1 h at 37 °C.
The cells were washed to remove unbound virus and fresh media was
added before incubating cells for 24 h at 37 °C. Cells were ﬁxed,
permeabilized and stained with DENV Mabs 4G2 or 2H2, both of
which bind to all four serotypes (Kraus et al., 2007). Cells were
analyzed with a FACScan ﬂow cytometer (Becton Dickinson) to
identify infected cells. The 50% neutralization titers were determined
by nonlinear dose–response regression analysis ((Prism Package,
GraphPad Software, Inc., San Diego, CA).
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